본문 바로가기
KERD
논문KCI 등재

Antidepressant Prescribing Patterns in Korea: Results from the Clinical Research Center for Depression Study

김재민|이민수|전태연|임현우|윤진상|김성완|정성원|신일선|배경열
대한신경정신의학회 (Korean Neuropsychiatric Association)|2011.09|PSYCHIATRY INVESTIGATION|제8권 제3호|pp. 234-244

2

조회

0

다운로드

4

인용

0

참고문헌

키워드

KoreaDepressionAntidepressive agentsPrescriptionsCRESCEND.
주제분류정신과학

초록

Objective This study aimed to investigate antidepressant prescribing patterns, including initial choice, switching and combining, and concomitant use of non-antidepressant agents, for depressive disorders in naturalistic clinical care settings in Korea. Methods Patients with depressive disorder were recruited from both outpatient and inpatient settings in 18 hospitals from all over Korea. Treatment was performed in naturalistic patterns based on each clinician’s decision. Data were collected on the prescription of antidepressants and concomitant agents from baseline to 12-week follow-up. Results Selective serotonin reuptake inhibitors (SSRIs) were the most commonly prescribed initial antidepressant (48.9%), followed by newer dual-action antidepressants (45.8%). When an SSRI was the initial antidepressant, 46.2% of patients whose medication was changed were moved to newer dual-action antidepressants, and 67.4% of combination cases were combined with newer dual-action ones. When a newer dual-action antidepressant was the initial antidepressant, 70.6% of patients whose medication was changed were moved to SSRIs, and other antidepressants including tricyclic antidepressants were most commonly added for combination treatment (50% of combination cases). During the treatment period, 20.6% of antidepressants prescribed were augmented by non-antidepressant agents, and 75.1% were used concomitantly with anxiolytics or hypnotics. The most commonly used concomitant non-antidepressant agent was quetiapine. Conclusion The selection of antidepressants and the concomitant use of non-antidepressant agents are becoming increasingly diversified, and the results of this study reflect changes in the prescribing pattern in actual Korean practices.

Abstract

Objective This study aimed to investigate antidepressant prescribing patterns, including initial choice, switching and combining, and concomitant use of non-antidepressant agents, for depressive disorders in naturalistic clinical care settings in Korea. Methods Patients with depressive disorder were recruited from both outpatient and inpatient settings in 18 hospitals from all over Korea. Treatment was performed in naturalistic patterns based on each clinician’s decision. Data were collected on the prescription of antidepressants and concomitant agents from baseline to 12-week follow-up. Results Selective serotonin reuptake inhibitors (SSRIs) were the most commonly prescribed initial antidepressant (48.9%), followed by newer dual-action antidepressants (45.8%). When an SSRI was the initial antidepressant, 46.2% of patients whose medication was changed were moved to newer dual-action antidepressants, and 67.4% of combination cases were combined with newer dual-action ones. When a newer dual-action antidepressant was the initial antidepressant, 70.6% of patients whose medication was changed were moved to SSRIs, and other antidepressants including tricyclic antidepressants were most commonly added for combination treatment (50% of combination cases). During the treatment period, 20.6% of antidepressants prescribed were augmented by non-antidepressant agents, and 75.1% were used concomitantly with anxiolytics or hypnotics. The most commonly used concomitant non-antidepressant agent was quetiapine. Conclusion The selection of antidepressants and the concomitant use of non-antidepressant agents are becoming increasingly diversified, and the results of this study reflect changes in the prescribing pattern in actual Korean practices.

참고문헌 (54)

  1. Kessler RC, "Lifetime and 12-month prevalence of DSM-III-R psychiatric disorders in the United States. Results from the National Comorbidity Survey", Arch Gen Psychiatry, 51, pp.8~19 (1994)
  2. Wells KB, "Functioning and utility for current health of patients with depression or chronic medical conditions in managed, primary care practices", Arch Gen Psychiatry, 56, pp.897~904 (1999)
  3. Hirschfeld RM, "Social functioning in depression: a review", J Clin Psychiatry, 61, pp.268~275 (2000)
  4. Kim JM, "Interactions between life stressors and susceptibility genes (5-HTTLPR and BDNF) on depression in Korean elders", BIOLOGICAL PSYCHIATRY, 62(5), pp.423~428 (2007), ELSEVIER SCIENCE INC
  5. Lawrenson RA, "The treatment of depression in UK general practice: selective serotonin reuptake inhibitors and tricyclic antidepressants compared", J Affect Disord, 59, pp.149~157 (2000)
  6. Anderson IM, "Evidence-based guidelines for treating depressive disorders with antidepressants: a revision of the 2000 British Association for Psychopharmacology guidelines", J Psychopharmacol, 22, pp.343~396 (2008)
  7. Anderson IM, "Selective serotonin reuptake inhibitors versus tricyclic antidepressants: a meta-analysis of efficacy and tolerability", J Affect Disord, 58, pp.19~36 (2000)
  8. MacGillivray S, "Efficacy and tolerability of selective serotonin reuptake inhibitors compared with tricyclic antidepressants in depression treated in primary care: systematic review and mbeta-analysis", BMJ, 326, pp.1014~ (2003)
  9. Papakostas GI, "Are antidepressant drugs that combine serotonergic and noradrenergic mechanisms of action more effective than the selective serotonin reuptake inhibitors in treating major depressive disorder? A meta-analysis of studies of newer agents", Biol Psychiatry, 62, pp.1217~1227 (2007)
  10. ewski SR, "Acceptability of second-step treatments to depressed out patients: a STAR*D report", Am J Psychiatry, 164, pp.753~760 (2007)
  11. American Psychiatric Association, "Practice guideline for the treatment of patients with major depressive disorder (revision)", Am J Psychiatry, 157, pp.1~45 (2000)
  12. Bauer M, "World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Unipolar Depressive Disorders in Primary Care", World J Biol Psychiatry, 8, pp.67~104 (2007)
  13. Bauer M, "Prescribing patterns of antidepressants in Europe: results from the Factors Influencing Depression Endpoints Research (FINDER) study", Eur Psychiatry, 23, pp.66~73 (2008)
  14. Bauer M, "World Federation of Societies Biological Psychiatry Task Force on Treatment Guidelines for Unipolar Depressive Disorders. World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Unipolar Depressive Disorders, Part 1: Acute and continuation treatment of major depressive disorder", World J Biol Psychiatry, 3, pp.5~43 (2002)
  15. 이민수, "Predictors of 12-week remission in a nationwide cohort of people with depressive disorders: the CRESCEND study", Hum. Psychopharmacol.-Clin. Exp., 26(1), pp.41~50
  16. American Psychiatric Association, "Diagnostic and Statistical Manual of Mental Disorders" (1994), American Psychiatric Association
  17. Hamilton MA, "A rating scale for depression", J Neurol Neurosurg Psychiatry, 23, pp.56~62 (1960)
  18. First MB, "User’s Guide for the Structured Clinical Interview for DSM-IV Axis I Disorders Research Version (SCID-I)" (1996), New York State Psychiatric Institute, Biometrics Research
  19. Hamilton M, "The assessment of anxiety states by rating", Br J Med Psychol, 32, pp.50~55 (1959)
  20. Guy W, "ECDEU Assessment Manual for Psychopharmacology" (1976), National Institute of Mental Health
  21. 이준영, "총괄기능평가척도(Global Assessment of Functioning Scale)와 사회적, 직업적 기능평가척도(Social and Occupational Functioning Scale)", 대한정신약물학회지, 17(2), pp.122~127 (2006), 대한정신약물학회
  22. 이중서, "한국판 Hamilton 우울증 평가 척도의 신뢰도, 타당도 연구", 신경정신의학, 44(4), pp.456~465 (2005), 대한신경정신의학회
  23. 정한용, "치료 저항성 우울증 환자에 대한 한국 정신과 의사들의 약물치료 전략", 대한정신약물학회지, 14(1), pp.40~47 (2003), 대한정신약물학회
  24. Watanabe N, "Safety reporting and adverse-event profile of mirtazapine described in randomized controlled trials in comparison with other classes of antidepressants in the acute-phase treatment of adults with depression: systematic review and meta-analysis", CNS Drugs, 24, pp.35~53 (2010)
  25. Thase ME, "Remission with mirtazapine and selective serotonin reuptake inhibitors: a meta-analysis of individual patient data from 15 controlled trials of acute-phase treatment of major depression", Int Clin Psychopharmacol, 25, pp.189~198 (2010)
  26. Bauer M, "The effect of venlafaxine compared with other antidepressants and placebo in the treatment of major depression: a meta-analysis", Eur Arch Psychiatry Clin Neurosci, 259, pp.172~185 (2009)
  27. Howell C, "Cardiovascular toxicity due to venlafaxine poisoning in adults: a review of 235 consecutive cases", Br J Clin Pharmacol, 64, pp.192~197 (2007)
  28. Stahl SM, "Comparative efficacy between venlafaxine and SSRIs: a pooled analysis of patients with depression", Biol Psychiatry, 52, pp.1166~1174 (2002)
  29. Gutierrez MA, "Venlafaxine: a 2003 update", Clin Ther, 25, pp.2138~2154 (2003)
  30. 서정석, "한국형 우울장애 약물치료 알고리듬 2006 (Ⅰ)", 신경정신의학, 46(5), pp.453~460 (2007), 대한신경정신의학회
  31. National Institute for Clinical Excellence, "Depression: Management of Depression in Primary and Secondary Care, in Clinical Guideline 23" (2004), National Institute for Clinical Excellence
  32. 서호준, "주요 우울장애 입원환자에서 약물 사용의 변화: 일 대학병원에서 2001년과 2006년의 비교", 대한정신약물학회지, 18(6), pp.399~407 (2007), 대한정신약물학회
  33. Nakajima S, "Accelerating response to antidepressant treatment in depression: a review and clinical suggestions", Prog Neuropsychopharmacol Biol Psychiatry, 34, pp.259~264 (2010)
  34. Katz MM, "Onset and early behavioral effects of pharmacologically different antidepressants and placebo in depression", Neuropsychopharmacology, 29, pp.566~579 (2004)
  35. Szegedi A, "Early improvement in the first 2 weeks as a predictor of treatment outcome in patients with major depressive disorder: a meta-analysis including 6562 patients", J Clin Psychiatry, 70, pp.344~353 (2009)
  36. Horgan D, "A survey of combination antidepressant use in Australia", Australas Psychiatry, 15, pp.26~29 (2007)
  37. Rush AJ, "Limitations in efficacy of antidepressant monotherapy", J Clin Psychiatry, 68(10), pp.8~10 (2007)
  38. Blier P, "Combination of antidepressant medications from treatment initiation for major depressive disorder: a double-blind randomized study", Am J Psychiatry, 167, pp.281~288 (2010)
  39. Stahl SM, "Combining antidepressant therapies from the initiation of treatment: a paradigm shift for major depression", J Clin Psychiatry, 70, pp.1493~1494 (2009)
  40. de la Gándara J, "Use of antidepressant combinations: which, when and why? Results of a Spanish survey", Acta Psychiatr Scand Suppl, 428, pp.32~36 (2005)
  41. Zisook S, "Use of bupropion in combination with serotonin reuptake inhibitors", Biol Psychiatry, 59, pp.203~210 (2006)
  42. Bodkin JA, "Combining serotonin reuptake inhibitors and bupropion in partial responders to antidepressant monotherapy", J Clin Psychiatry, 58, pp.137~145 (1997)
  43. Garattini S, "Biochemical hypotheses on antidepressant dr-ugs: a guide for clinicians or a toy for pharmacologists", Psychol Med, 18, pp.287~304 (1988)
  44. DeBattista C, "Utility of atypical antipsychotics in the treatment of resistant unipolar depression", CNS Drugs, 23, pp.369~377 (2009)
  45. Pae CU, "Quetiapine XR: current status for the treatment of major depressive disorder", Prog Neuropsychopharmacol Biol Psychiatry, 34, pp.1165~1173 (2010)
  46. Figueroa C, "Pharmacokinetic profiles of extended release quetiapine fumarate compared with quetiapine immediate release", Prog Neuropsychopharmacol Biol Psychiatry, 33, pp.199~204 (2009)
  47. Yatham LN, "Atypical antipsychotics in bipolar depression: potential mechanisms of action", J Clin Psychiatry, 66(5), pp.40~48 (2005)
  48. Ichikawa J, "5-HT(2A) and D(2) receptor blockade increases cortical DA release via 5-HT(1A) receptor activation: a possible mechanism of atypical antipsychotic-induced cortical dopamine release", J Neurochem, 76, pp.1521~1531 (2001)
  49. Rihmer Z, "Antidepressive efficacy of quetiapine XR in unipolar major depression--the role of early onset of action and sleep-improving effect in decreasing suicide risk", Neuropsychopharmacol Hung, 11, pp.211~215 (2009)
  50. Landen M, "A randomized, double-blind, placebo-controlled trial of buspirone in combination with an SSRI in patients with treatment-refractory depression", J Clin Psychiatry, 59, pp.664~668 (1998)
  51. Carvalho AF, "Augmentation strategies for treatment-resistant depression", Curr Opin Psychiatry, 22, pp.7~12 (2009)
  52. 이민수, "Relationship Between a History of a Suicide Attempt and Treatment Outcomes in Patients With Depression", J. Clin. Psychopharmacol., 31(4), pp.449~456
  53. Fava M, "Eszopiclone co-administered with fluoxetine in patients with insomnia coexisting with major depressive disorder", Biol Psychiatry, 59, pp.1052~1060 (2006)
  54. Furukawa TA, "Antidepressant and benzodiazepine for major depression", Cochrane Database Syst Rev, 1, pp.CD001026~ (2002)

관련 논문AI추천

근거중심 한국형 우울증 약물학적 치료지침, 개정판(III) : 항우울제의 증량, 교체, 병합 및 강화요법고영훈, 구재우, 박선철, 박용천, 백종우, 성승환, 심세훈, 오강섭, 원은수, 이강준, 이경민, 이문수, 이민수, 이화영, 이희영, 전홍진, 최준호, 한규만, 한상우, 한창수, 함병주, 황태연대한신경정신의학회 · 신경정신의학2013 · 제52권 제5호근거중심 한국형 우울증 약물학적 치료지침, 개정판 (I) : 항우울제 치료의 초기선택고영훈, 박선철, 박용천, 백종우, 성승환, 심세훈, 오강섭, 원은수, 이강준, 이문수, 이민수, 이화영, 이희영, 전홍진, 최준호, 한규만, 한상우, 한창수, 함병주, 황태연대한신경정신의학회 · 신경정신의학2013 · 제52권 제4호한국형 우울장애 약물치료 알고리듬 2025 (II): 임상 아형김원, 김낙영, 김문두, 민경준, 박성용, 박원명, 서정석, 성형모, 양찬모, 왕성민, 우영섭, 윤보현, 이정구, 전덕인, 정영은, 정종현, 최원석대한신경정신의학회 · 신경정신의학2025 · 제64권 제3호조현병 환자에서 항우울제 사용 분석 : 임상적 관련인자 및 처방현황강시현, 김정원, 박동연, 이종일, 최진영대한신경정신의학회 · 신경정신의학2017 · 제56권 제4호Korean Medication Algorithm for Depressive Disorder: Comparisons with Other Treatment Guidelines김원, 민경준, 박영민, 박원명, 서정석, 송후림, 왕희령, 우영섭, 이황빈, 임은성, 전덕인, 정종현, 홍정완, 홍진표대한신경정신의학회 · PSYCHIATRY INVESTIGATION2014 · 제11권 제1호한국형 우울장애 약물치료 알고리듬 2025 (I): 주요우울삽화의 치료전략김원, 김낙영, 김문두, 민경준, 박성용, 박원명, 서정석, 성형모, 심세훈, 양찬모, 왕성민, 우영섭, 윤보현, 이상열, 이정구, 전덕인, 정영은, 정종현, 최원석대한신경정신의학회 · 신경정신의학2025 · 제64권 제3호

이 간행물의 다른 논문 (6건)

Prevalence and Correlates of Psychiatric Symptoms in North Korean Defectors배승민, 김정은, 이유진, 김석주, 조성진, 김하경, 김효현pp. 179-185Anger in Elderly Patients with Depressive DisordersSengmi Baeg, 왕성근, 지익성, 김정란, Soo Yeong Kimpp. 186-193Associated Factors of Quality of Life in First-Episode Schizophrenia Patients이수영, 안석균, 강지인, 박진영, 김경란, 이은, 권준수, 송윤영pp. 201-206Reduced Fertility and Fecundity among Patients with Bipolar I Disorder and Schizophrenia in EgyptAhmed Eissa, Vishwajit L. Nimgaonkar, Hader Mansour, Kareem Kandil, Warda Fathi, Mai Elassy, Ibtihal Ibrahim, Hala Salah, Amal Yassin, Hanan Elsayed, Salwa Tobar, Hala El-Boraie, Mohamed Elhadidy, Nahed E. Ibrahim, Wafaa El-Bahaeipp. 214-220Performance Enhancement with Low Stress and Anxiety Modulated by Cognitive FlexibilityLeonard Zaichkowsky, Do-Hyun E. Na, Churl Na, Hyung Woo Park, Baik Seok Kee, 한덕현pp. 221-226
원문 보기